For the year ending 2025-12-31, BHIC had -$592 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 642,090 |
| Lease cost, net of repayments | 61,236 |
| Accounts receivable | 298,972 |
| Inventory | 278,029 |
| Deferred revenue | 112,261 |
| Deferred tax | 2,069 |
| Accrued expenses | 1,964 |
| Accounts payable | -1,952 |
| Deposits | 4,400 |
| Income tax payable | 79,030 |
| Prepaid expenses | 16,509 |
| Net cash provided by operating activities | 172,178 |
| Purchase of intangible assets | 56,850 |
| Advances from related parties | 3,046,080 |
| Repayment to related parties | 3,162,000 |
| Proceeds from the sale of common stock | 0 |
| Net cash provided by financing activities | -115,920 |
| Net increase in cash | -592 |
| Cash at beginning of period | 662,517 |
| Cash at end of period | 661,925 |
BioScience Health Innovations, Inc. (BHIC)
BioScience Health Innovations, Inc. (BHIC)